Cabozantinib is a targeted therapy used to treat many forms of cancers. Prof. Robert Jones (University of Glasgow, Scotland, United Kingdom) discusses the rationale, design, and findings of the randomised phase 2 ATLANTIS trial, of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma.
- What is the rationale for the use of cabozantinib in the treatment of metastatic urothelial cancer? (00:12-01:05)
- What makes the ATLANTIS clinical trial design unique? (01:05-02:32)
- What were the efficacy and safety findings of the ATLANTIS cabozantinib comparison? (02:32-03:40)
The abstract entitled: ‘A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison’ was presented at the ASCO annual meeting, June 3-7, 2022.
Disclosures: Robert Jones has received grant/research support from Astellas, AstraZeneca, Clovis, Exelixis and Roche. He is on the Advisory Board for Astellas, AstraZeneca, BMS, Clovis, Merck Serono, MSD, Pfizer, QED and Roche. He has received honoraria/honorarium from Astellas, AstraZeneca, BMS, Clovis, Merck Serono, MSD, Pfizer and Roche.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
Share this Video
Related Videos In Genitourinary Cancer
Sebastian Schmid, ESMO 2022: RACE-IT – RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer
Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy following radical cystectomy in patients with locally […]
Jonathan Rosenberg, ESMO 2022: Study EV-103 Cohort K – Enfortumab vedotin in combination with pembrolizumab in locally advanced or metastatic urothelial cancer
As there is a current need for effective and tolerable first line treatment options in patients with locally advanced or metastatic urothelial cancer (la/mUC), Dr Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, NY, USA) joins touchONCOLOGY to discuss the positive results from Study EV-103 Cohort K. The study data supports ongoing investigations of […]
Enrique Grande, ESMO 2022: Post-hoc analysis investigating PD-L1 expression on immune cells, and improved OS with atezolizumab in patients with urothelial cancer
PD-L1 assays use various methods to predict PD-L1/PD-1 blockade outcomes, recent data suggests clinically relevant PD-L1–expressing immune cells are dendritic cells. Dr Enrique Grande Pulido (MD Anderson Cancer Centre Madrid, Madrid, Spain) joins touchONCOLOGY to discuss a post-hoc analysis investigating PD-L1 expression on immune cells by SP142 co-localises with dendritic cells, and the associated improved overall […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!